What laboratory workup should be ordered for a patient with biliary colic and hepatic steatosis (fatty liver)?

Laboratory Workup for Biliary Colic with Hepatic Steatosis

Order a comprehensive metabolic panel including liver enzymes (ALT, AST), complete metabolic profile, lipid panel, and calculate FIB-4 score as your initial laboratory assessment, followed by risk-stratified noninvasive fibrosis testing based on metabolic risk factors. 1

Initial Laboratory Panel

Essential Baseline Tests

• Liver enzymes: ALT and AST to assess hepatocellular injury and calculate the AST:ALT ratio 2

  • ALT >20 U/L for women or >30 U/L for men indicates chronic hepatitis requiring further evaluation 1
  • AST:ALT ratio <1 suggests metabolic disease-related fatty liver, while >2 suggests alcohol-induced disease 2

• Complete metabolic panel including:

  • Total bilirubin (assess biliary obstruction from colic) 3
  • Alkaline phosphatase (ALP) - elevated in biliary disease 4
  • Albumin (assess synthetic liver function) 3
  • Glucose and HbA1c (screen for diabetes, a major risk factor) 1, 5

• Lipid panel: Total cholesterol, HDL-C, LDL-C, and triglycerides 1, 4

  • Essential for calculating hepatic steatosis index and assessing cardiovascular risk 6

• Additional screening tests:

  • Fasting insulin (assess insulin resistance) 7
  • Platelet count (needed for FIB-4 calculation) 1
  • BUN (assess overall metabolic status) 3

Risk Stratification for Fibrosis

Calculate FIB-4 Score First

FIB-4 serves as the first-line point-of-care test for fibrosis risk stratification 1:

• FIB-4 <1.3 (or <2.0 if age >65 years): Low risk, exclude advanced fibrosis with high negative predictive value; reassess every 2 years 1
• FIB-4 ≥1.3: Proceed to secondary noninvasive testing 1

Secondary Noninvasive Testing (if FIB-4 ≥1.3)

Perform one of the following based on availability 1:

• Enhanced Liver Fibrosis (ELF) score
• Vibration-controlled transient elastography (VCTE/FibroScan)
• Magnetic resonance elastography (MRE)

Risk thresholds for secondary tests 1:

• Low risk: ELF <7.7, VCTE <8.0 kPa, MRE <2.6 kPa
• Intermediate risk: ELF 7.7-9.8, VCTE 8.1-12 kPa, MRE 2.6-3.6 kPa
• High risk/Advanced fibrosis: ELF >9.8, VCTE >12 kPa, MRE >3.6 kPa
• Cirrhosis: ELF >11.3, VCTE >15 kPa, MRE >4.6 kPa

Metabolic Risk Factor Assessment

Patients with type 2 diabetes or ≥2 metabolic syndrome features require sequential testing with a second noninvasive test regardless of initial FIB-4 1:

• Hypertension
• Obesity (BMI ≥30 kg/m²)
• Dyslipidemia
• Insulin resistance/prediabetes

Exclude Alternative Liver Disease Causes

Screen for other chronic liver diseases if aminotransferases are elevated 1:

• Hepatitis B surface antigen and antibody
• Hepatitis C antibody
• Ferritin and transferrin saturation (hemochromatosis)
• Antinuclear antibody, anti-smooth muscle antibody (autoimmune hepatitis)
• Ceruloplasmin (Wilson disease if age <40)
• Alpha-1 antitrypsin level
• Alcohol use assessment (detailed history)

Optional Calculated Indices

Hepatic Steatosis Index (HSI) can be calculated using available data 6:

• HSI = 8 × (ALT/AST ratio) + BMI (+2 if female; +2 if diabetes)
• HSI <30.0: Rules out NAFLD with 93.1% sensitivity
• HSI >36.0: Detects NAFLD with 92.4% specificity

Surveillance for Advanced Disease

If noninvasive tests suggest advanced fibrosis (F3) or cirrhosis (F4), initiate surveillance 1:

• Hepatocellular carcinoma screening (ultrasound + AFP every 6 months)
• Esophageal variceal screening per Baveno criteria
• Refer to hepatology/gastroenterology specialist

Critical Pitfalls to Avoid

• Do not rely on ultrasound alone for fibrosis assessment - it detects steatosis but cannot reliably stage fibrosis 2
• Do not use FIB-4 cutoff of 1.3 in patients >65 years - use 2.0 instead to avoid false positives 1
• Do not skip metabolic screening - diabetes and metabolic syndrome dramatically increase fibrosis risk and warrant more aggressive testing 1, 5
• Consider liver biopsy when noninvasive tests are discordant or indeterminate 1